ATE402700T1 - Glycinamid-derivate als raf-kinase-hemmer - Google Patents
Glycinamid-derivate als raf-kinase-hemmerInfo
- Publication number
- ATE402700T1 ATE402700T1 AT03790841T AT03790841T ATE402700T1 AT E402700 T1 ATE402700 T1 AT E402700T1 AT 03790841 T AT03790841 T AT 03790841T AT 03790841 T AT03790841 T AT 03790841T AT E402700 T1 ATE402700 T1 AT E402700T1
- Authority
- AT
- Austria
- Prior art keywords
- raf
- kinase inhibitors
- glycinamide derivatives
- glycinamide
- derivatives
- Prior art date
Links
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical class NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 102000009929 raf Kinases Human genes 0.000 title 1
- 108010077182 raf Kinases Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02019023 | 2002-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE402700T1 true ATE402700T1 (de) | 2008-08-15 |
Family
ID=31970263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03790841T ATE402700T1 (de) | 2002-08-27 | 2003-07-31 | Glycinamid-derivate als raf-kinase-hemmer |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7476683B2 (de) |
| EP (1) | EP1531817B1 (de) |
| JP (1) | JP2005539041A (de) |
| CN (1) | CN1678314A (de) |
| AR (1) | AR043047A1 (de) |
| AT (1) | ATE402700T1 (de) |
| AU (1) | AU2003250197B2 (de) |
| CA (1) | CA2496688C (de) |
| DE (1) | DE60322544D1 (de) |
| ES (1) | ES2311120T3 (de) |
| WO (1) | WO2004019941A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP2298311B1 (de) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| CA2526285A1 (en) | 2003-05-15 | 2004-12-23 | Arqule, Inc. | Inhibitors of p38 and methods of using the same |
| EP1636585B2 (de) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl-harnstoffe mit kinasehemmender wirkung |
| WO2005005389A2 (en) * | 2003-07-07 | 2005-01-20 | Merck Patent Gmbh | Malonamide derivatives |
| PL1663978T3 (pl) | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
| EP1692110A1 (de) * | 2003-12-10 | 2006-08-23 | MERCK PATENT GmbH | Diacylhydrazinderivate |
| US7838524B2 (en) | 2004-04-30 | 2010-11-23 | Bayer Healthcare Llc | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| WO2006010082A1 (en) | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
| CA2584368A1 (en) | 2004-10-19 | 2006-04-27 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
| AU2006204724A1 (en) | 2005-01-14 | 2006-07-20 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
| AR057455A1 (es) * | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
| WO2008046216A1 (en) * | 2006-10-18 | 2008-04-24 | Methylgene, Inc. | Kinase inhibitors and uses thereof |
| WO2011044327A1 (en) | 2009-10-07 | 2011-04-14 | Medivation Prostate Therapeutics, Inc. | Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds |
| AU2011302295B2 (en) | 2010-09-13 | 2015-08-20 | Microbiotix, Inc. | Inhibitors of viral entry into mammalian cells |
| RU2670982C2 (ru) * | 2013-05-08 | 2018-10-29 | Киссеи Фармасьютикал Ко., Лтд. | ПРОИЗВОДНЫЕ α-ЗАМЕЩЕННОГО ГЛИЦИНАМИДА |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5334716A (en) * | 1991-06-17 | 1994-08-02 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic derivatives |
| TW257757B (de) | 1993-03-03 | 1995-09-21 | Boehringer Mannheim Gmbh | |
| SK281433B6 (sk) * | 1994-04-14 | 2001-03-12 | Glaxo Wellcome Inc. | 5-heterocyklo-1,5-benzodiazepínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie |
| US5741926A (en) * | 1997-02-12 | 1998-04-21 | Shaman Pharmaceuticals, Inc. | Aniline derivatives having antihyperglycemic activity |
| WO2000026197A1 (en) * | 1998-10-29 | 2000-05-11 | Bristol-Myers Squibb Company | Novel inhibitors of impdh enzyme |
| CA2397575A1 (en) * | 2000-01-13 | 2001-07-19 | Tularik Inc. | Antibacterial agents |
| US7301023B2 (en) * | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
-
2003
- 2003-07-31 AT AT03790841T patent/ATE402700T1/de not_active IP Right Cessation
- 2003-07-31 ES ES03790841T patent/ES2311120T3/es not_active Expired - Lifetime
- 2003-07-31 EP EP03790841A patent/EP1531817B1/de not_active Expired - Lifetime
- 2003-07-31 CA CA2496688A patent/CA2496688C/en not_active Expired - Fee Related
- 2003-07-31 DE DE60322544T patent/DE60322544D1/de not_active Expired - Lifetime
- 2003-07-31 AU AU2003250197A patent/AU2003250197B2/en not_active Ceased
- 2003-07-31 US US10/526,043 patent/US7476683B2/en not_active Expired - Fee Related
- 2003-07-31 CN CNA038205718A patent/CN1678314A/zh active Pending
- 2003-07-31 WO PCT/EP2003/008474 patent/WO2004019941A1/en not_active Ceased
- 2003-07-31 JP JP2004531844A patent/JP2005539041A/ja active Pending
- 2003-08-27 AR ARP030103089A patent/AR043047A1/es unknown
-
2008
- 2008-11-18 US US12/273,040 patent/US20090163556A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2496688C (en) | 2012-09-25 |
| WO2004019941A1 (en) | 2004-03-11 |
| EP1531817B1 (de) | 2008-07-30 |
| US20090163556A1 (en) | 2009-06-25 |
| US20060167261A1 (en) | 2006-07-27 |
| US7476683B2 (en) | 2009-01-13 |
| ES2311120T3 (es) | 2009-02-01 |
| DE60322544D1 (de) | 2008-09-11 |
| AU2003250197A1 (en) | 2004-03-19 |
| JP2005539041A (ja) | 2005-12-22 |
| AU2003250197B2 (en) | 2009-11-12 |
| EP1531817A1 (de) | 2005-05-25 |
| CA2496688A1 (en) | 2004-03-11 |
| AR043047A1 (es) | 2005-07-13 |
| CN1678314A (zh) | 2005-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60315862D1 (de) | Dihydropyridinonderivate als hne-inhibitoren | |
| ATE452891T1 (de) | Pyrimidopyrimidone als kinaseinhibitoren | |
| ATE368651T1 (de) | Pyridazinon-derivate als gsk-3beta-hemmer | |
| DE60320933D1 (de) | Rho-kinase inhibitoren | |
| ATE416171T1 (de) | 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren | |
| ATE478870T1 (de) | Spiroindolinpiperidinderivate | |
| ATE460418T1 (de) | Heterocyclocarboxamidderivate | |
| DK1551802T3 (da) | Indol-3-svovlderivater | |
| ATE467631T1 (de) | Chinuclidinamidderivate | |
| DE60301683D1 (de) | Leseverstärker | |
| ATE443054T1 (de) | Cyano-pyrrolidine als dpp-iv inhibitoren | |
| ATE438644T1 (de) | Chinazolinderivate | |
| IS7720A (is) | Píperidín-N-oxíð-afleiður | |
| DK1474408T3 (da) | N-Phenyl-2-pyrimidinaminderivater | |
| NO20043642L (no) | Heterocykiske tripeptider som hepatitt C inhibitorer | |
| ATE499347T1 (de) | Amidderivate | |
| EP1499336A4 (de) | Proteasehemmer | |
| DE602004018837D1 (de) | Ptidase-iv-inhibitoren | |
| DE60324208D1 (de) | Biarylsulfonamide als mmp-inhibitoren | |
| ATE538787T1 (de) | Benzimidazol-derivative als raf-kinase-hemmer | |
| DK1652843T3 (da) | Amidderivater | |
| DE60322544D1 (de) | Glycinamid-derivate als raf-kinase-hemmer | |
| ATE440821T1 (de) | Isochinolinderivate als mao-b inhibitoren | |
| DE60307512D1 (de) | 3h-chinazoline -4-on derivaten | |
| ATE423771T1 (de) | Tetrahydrochinolinderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |